Cell News and Research

RSS

Exiqon completes discovery phase program for early detection of colorectal cancer in blood

Exiqon A/S today announced the completion of the discovery phase in its program for early detection of colorectal cancer in blood.

21 Dec 2010

Laser restoration therapy promotes hair regrowth in women

Many Women suffering from hair loss are turning to Advanced Hair Studios and discovering advanced laser therapy as a method along with other procedures to overcome thinning hair.

21 Dec 2010

Study reveals novel role of adenosine signaling in sickle cell disease

Metabolon, Inc., the leader in metabolomics, biomarker discovery and analysis, announces the publication of "Novel Role of Adenosine Signaling in Sickle Cell Disease", in Nature Medicine. Application of non-targeted biochemical profiling (metabolomics) to a mouse model of sickle cell disease (SCD) revealed a detrimental role of adenosine signaling in SCD and suggested novel therapeutic targets. The study was carried out in collaboration with The University of Texas Health Science Center at Houston.

21 Dec 2010

Amylin submits metreleptin rolling submission BLA for treatment of rare forms of lipodystrophy

Amylin Pharmaceuticals, Inc. today announced that it has submitted the initial sections of a rolling submission for a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the use of metreleptin to treat diabetes and/or hypertriglyceridemia (high levels of triglycerides in the bloodstream) in patients with rare forms of lipodystrophy.

21 Dec 2010

FMCNA recommends dialysis patients to take precautions during severe weather

Fresenius Medical Care North America, the nation's leading network of dialysis facilities, reminds dialysis patients to take precautions now so they are not caught off guard when severe weather hits in their home community.

21 Dec 2010

New research sheds light on complex regulatory pathways for effective innate immune system

New research by scientists at the University of California, San Diego School of Medicine and Skaggs School of Pharmacy and Pharmaceutical Sciences reveals that the immune system has an effective backup plan to protect the body from infection when the "master regulator" of the body's innate immune system fails.

21 Dec 2010

Deinove to receive European patent for genetic engineering process

Deinove, the world's leading specialist in Deinococcus bacteria for biofuels, green chemistry and antibiotics, today announced that the European Patent Office had notified it of the intention to grant the patent application EP2016183 entitled "Process for chromosome engineering using a novel DNA repair system".

21 Dec 2010

Study: Chemotherapy can improve survival rate in older adolescents with leukemia

Research led by St. Jude Children-s Research Hospital investigators will likely impact how acute lymphoblastic leukemia is treated in young adults and shows older adolescent age does not dictate worse outcomes against the most common childhood cancer.

21 Dec 2010

New CPT code for use with T-SPOT.TB test

Oxford Immunotec, Inc. announces that a new and specific Current Procedural Terminology (CPT®) code has been established by the American Medical Association for use with the T-SPOT®.TB test. The new Category I code, 86481, is described as "Tuberculosis test, cell mediated immunity antigen response measurement; enumeration of gamma interferon-producing T-cells in cell suspension." This new code will be effective as of January 1, 2011.

21 Dec 2010

Researchers develop new lung imaging technique that causes minimum tissue disruption

Fast-moving objects create blurry images in photography, and the same challenge exists when scientists observe cellular interactions within tissues constantly in motion, such as the breathing lung. In a recent UCSF-led study in mice, researchers developed a method to stabilize living lung tissue for imaging without disrupting the normal function of the organ.

21 Dec 2010

Positive results from Incyte's COMFORT-I INCB18424 pivotal Phase III clinical trial in myelofibrosis

Incyte Corporation announced today positive top-line results from COMFORT-I, the pivotal Phase III clinical trial of INCB18424 (also known as INC424) in patients with myelofibrosis (MF) being conducted under a Food and Drug Administration (FDA) Special Protocol Assessment (SPA) Agreement. COMFORT-I (COntrolled MyeloFibrosis Study with ORal JAK Inhibitor Treatment) is a double-blind, placebo-controlled Phase III trial involving 309 patients.

21 Dec 2010

Researchers show how malaria parasites infect red blood cells, impede blood flow to organs

Although the incidence of malaria has declined in all but a few countries worldwide, according to a World Health Organization report earlier this month, malaria remains a global threat. Nearly 800,000 people succumbed to the mosquito-borne disease in 2009, nearly all of them in the developing world.

21 Dec 2010

Exome sequencing leads to correct diagnosis and life-saving treatment for mysterious genetic disorder

A genetic testing approach called exome sequencing—which provides a clinically practical alternative to whole-genome sequencing—led to correct diagnosis and life-saving treatment in a child with a previously unknown genetic disease, reports an upcoming paper in Genetics in Medicine, the official peer-reviewed journal of The American College of Medical Genetics (ACMG). The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

21 Dec 2010

Robotic surgery as effective as other minimally invasive techniques for head and neck squamous cell carcinomas

Less-invasive robotic surgery for upper airway and digestive track malignant tumors is as effective as other minimally invasive surgical techniques based on patient function and survival, according to University of Alabama at Birmingham researchers.

21 Dec 2010

Ambit commences Phase I advanced solid tumor trials for AC430 and AC480 inhibitors

Ambit Biosciences, today announced that it has initiated separate Phase I trials for two products AC430, a selective Janus Kinase 2 (JAK2) inhibitor, and AC480, a pan-HER inhibitor.

20 Dec 2010

VistaGen reports successful completion of AV-101 Phase 1 safety study for neuropathic pain

VistaGen Therapeutics, Inc., a stem cell technology company focused on drug discovery and development, today announced the successful completion of its initial Phase 1 safety study of AV-101, the Company's novel orally available prodrug candidate for treatment of neuropathic pain. Neuropathic pain, a serious and chronic condition causing pain after an injury or disease of the peripheral or central nervous system, affects approximately 1.8 million people in the U.S.

20 Dec 2010

Rexahn granted Japanese patent for preclinical compound RX-0047

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced that it was awarded patent 4,546,454 entitled, "Antisense Oligonucleotides that Inhibit Expression of HIF-1," by the Japanese Patent Office.

20 Dec 2010

Oncothyreon commences combination PX-866/cetuximab Phase 1/2 trial in cancers

Oncothyreon Inc. today announced enrollment of the first patient in a Phase 1/2 trial of PX-866 in combination with the chimeric monoclonal antibody cetuximab (Erbitux®). PX-866 is a small molecule compound designed to inhibit the activity of phosphatidylinositol-3-kinase (PI-3K), a component of an important cell survival signaling pathway.

20 Dec 2010

Fibrocell Science submits response to FDA CR letter for azficel-T BLA

Fibrocell Science, Inc., a biotechnology company focused on the development of autologous cell therapies for aesthetic, medical and scientific applications, announced today that it has submitted its complete response to the Complete Response (CR) letter issued by the U.S. Food & Drug Administration (FDA) regarding the Company's Biologics License Application (BLA) for azficel-T, proposed brand name laViv®, for the treatment of moderate to severe nasolabial folds and wrinkles.

20 Dec 2010

Exosomes derived from lymphoma, colorectal cancer patients circulated through Aethlon's Hemopurifier

Aethlon Medical, Inc., the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that it has demonstrated the ability to capture immunosuppressive exosomes derived from individuals with lymphoma and colorectal cancer.

20 Dec 2010

Cell News and Research

Exiqon completes discovery phase program for early detection of colorectal cancer in blood

Laser restoration therapy promotes hair regrowth in women

Study reveals novel role of adenosine signaling in sickle cell disease

Amylin submits metreleptin rolling submission BLA for treatment of rare forms of lipodystrophy

FMCNA recommends dialysis patients to take precautions during severe weather

New research sheds light on complex regulatory pathways for effective innate immune system

Deinove to receive European patent for genetic engineering process

Study: Chemotherapy can improve survival rate in older adolescents with leukemia

New CPT code for use with T-SPOT.TB test

Researchers develop new lung imaging technique that causes minimum tissue disruption

Positive results from Incyte's COMFORT-I INCB18424 pivotal Phase III clinical trial in myelofibrosis

Researchers show how malaria parasites infect red blood cells, impede blood flow to organs

Exome sequencing leads to correct diagnosis and life-saving treatment for mysterious genetic disorder

Robotic surgery as effective as other minimally invasive techniques for head and neck squamous cell carcinomas

Ambit commences Phase I advanced solid tumor trials for AC430 and AC480 inhibitors

VistaGen reports successful completion of AV-101 Phase 1 safety study for neuropathic pain

Rexahn granted Japanese patent for preclinical compound RX-0047

Oncothyreon commences combination PX-866/cetuximab Phase 1/2 trial in cancers

Fibrocell Science submits response to FDA CR letter for azficel-T BLA

Exosomes derived from lymphoma, colorectal cancer patients circulated through Aethlon's Hemopurifier

What are the challenges of cell line development? eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics